Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 5/20 | 0.38 |
| ▸ | SLC16A1 | P53985 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23402247 | 0.73 | ALDH1A1 (0.42) | SLC16A3SLC16A1ALDH1A1OPRM1HTT | |
| SCHEMBL7967384 | 0.72 | ALDH1A1 (0.36) | ALDH1A1P2RX7OPRM1CNR2MEN1 | |
| SCHEMBL23400335 | 0.71 | ALDH1A1 (0.40) | SLC16A3SLC16A1ALDH1A1CNR2HTT | |
| SCHEMBL23400782 | 0.70 | ALDH1A1 (0.41) | SLC16A3SLC16A1ALDH1A1HTTKMT2A | |
| SCHEMBL6490556 | 0.70 | P2RX7 (0.38) | ALDH1A1P2RX7CNR2MEN1HTT | |
| SCHEMBL6490137 | 0.69 | PTGS2 (0.38) | ALDH1A1CNR2 | |
| SCHEMBL23401795 | 0.69 | CNR2 (0.44) | SLC16A3SLC16A1ALDH1A1CNR2 | |
| SCHEMBL4918738 | 0.67 | ALDH1A1 (0.46) | ALDH1A1HTTKMT2ANPSR1 | |
| SCHEMBL6489297 | 0.66 | ALDH1A1 (0.39) | ALDH1A1P2RX7CNR2KMT2ANPSR1 | |
| SCHEMBL7984023 | 0.65 | PTGS2 (0.36) | ALDH1A1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6956053-B2 | Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands | THE JAMES BLACK FOUNDATION LIMITED (GB) | 2005-10-18 | — | — | US | disclosed |
| US-20030207874-A1 | Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands | JAMES BLACK FOUNDATION LIMITED, THE (GB) | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207874-A1 | Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands | CCKBR, GRPR, CCKAR | SLC16A3 3662/4885SLC16A1 3182/4885ALDH1A1 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.